Success story

Sêmeia

Artificial intelligence at the service of healthcare: a successful venture in Toulouse

Founded in 2017, the start-up Sêmeia has quickly established itself as a key player in e-health in France. Specialising in the remote monitoring of patients with chronic diseases, the company chose Toulouse as the location for its R&D centre. This strategic decision illustrates the strength of Toulouse’s healthcare and artificial intelligence ecosystem.

An ambitious young company serving patients

Founded in Paris, Sêmeia develops innovative digital solutions to improve the care of patients suffering from chronic or serious illnesses (kidney failure, diabetes, mental health disorders). Using artificial intelligence, its tools help doctors identify patients at risk of relapse or hospitalisation and personalise their follow-up care.

From the outset, the company has had a strong ambition: to transform the way health data is used to strengthen prevention and improve the quality of care.

Why Toulouse? A decisive choice

In 2018, Pierre Hornus, CEO of Sêmeia, explored the possibilities of setting up an R&D team in the region. After considering various options, including Bordeaux, Toulouse was ultimately chosen in 2019.
Several factors were decisive in this choice:

Excellence in artificial intelligence: the presence of major initiatives such as ANITI (Interdisciplinary Institute for Artificial Intelligence).
A cutting-edge healthcare ecosystem: potential collaborations with Toulouse University Hospital, Clinique Pasteur and major laboratories.
Competitive set-up costs promoting rapid growth.
Quality of life: a decisive asset for attracting and retaining talent.

Support from Toulouse Team – Invest

Toulouse Team – Invest played a decisive role. The team worked hard to convince Sêmeia’s executives, notably through a decisive meeting in Paris that showcased Toulouse’s strengths.
This support took the form of:

The provision of initial office space at Village by CA Toulouse, a partner accelerator offering collaborative space and a support programme.
Rapid integration into the local ecosystem with strategic connections in healthcare (CHU, Pierre Fabre), artificial intelligence (LAAS, IRIT) and with investors (Elaia).
Support in dealing with institutional players (ARS, GIP Esanté).
Promoting the quality of life in Toulouse to Parisian employees, facilitating their relocation.

Rapid growth in Toulouse

Since its establishment in 2019, Sêmeia has experienced sustained expansion:

Recruitment: from an initial three people, the Toulouse team now has nearly 30 employees from all over France.
Fundraising: an initial round in 2020, followed by a Series B round of €8 million in 2022 with the support of leading investors such as Orange Ventures Impact and Malakoff Humanis.
Strategic acquisition: acquisition of Optim’Care in 2022, consolidating its position in remote monitoring of kidney disease.
New premises: opening of an office in the heart of Toulouse in early 2023 to support its growth.

Pierre Hornus, CEO of Sêmeia, emphasizes the importance of choosing Toulouse:
“The health and artificial intelligence ecosystem in Toulouse, combined with the quality of life, was a major asset in convincing our teams. After 18 months, our growth is on track and our employees are delighted with their location in the Ville rose.”

Sêmeia

Our support

With its ecosystem of excellence, renowned quality of life, and tailored support from Toulouse Team – Invest, the Toulouse metropolitan area is a strategic choice for innovative companies looking to accelerate their development in Europe.

Would you like to set up your business in Toulouse and benefit from personalized support?

Toulouse Team – Invest by your side